Skip to main content
. 2017 Jun 13;31(4):357–367. doi: 10.1007/s40259-017-0232-7

Fig. 3.

Fig. 3

Response to first and second treatment courses according to European League Against Rheumatism criteria using C-reactive protein (efficacy population). Efficacy population for the first course included 100 patients in the CT-P10 and 48 patients in the innovator rituximab treatment groups. Of these, 82 patients received a second course of treatment (59 and 23 patients in the CT-P10 and innovator rituximab treatment groups, respectively). RTX innovator rituximab